207 Cytogenetic Aberrations in Young Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. (11th January 2018)

• Record Type: Journal Article
• Authors: Liao, Guanghong; Sajjan, Sujata; Yang, Tianyu; Sheikh-Fayyaz, Silvat; Haghi, Nina; Zhang, Xinmin; Wang, Jing; Chen, Brian; Brody, Judith; Reddy, Kalpana; Hsu, Peihong
• Is Part Of: American journal of clinical pathology. Volume 149(2018)Supplement 1
• Page Start: S88
• Page End: S88
• Publication Date: 2018-01-11
• Subjects: Diagnosis, Laboratory -- Periodicals; Pathology -- Periodicals; 616.07
• DOI: 10.1093/ajcp/aqx121.206
• Languages: English
• ISSNs: 0002-9173

Abstract

Abstract: Objectives: Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is a low-grade B-cell hematologic malignancy with high global prevalence. Half the patients have somatic mutations, as demonstrated by fluorescence in situ hybridization (FISH) interphase analysis in over 80% of these cases. Del 11q22-23, TP53/17p deletion and del 6q are clinically significant high-risk prognostic factors. Few studies show that 10%-20% of patients are younger than 55 years, and their prognosis differs from older patients because of their longer survival. Methods: We retrospectively reviewed FISH studies in 800 patients with CLL/SLL diagnosed in our health system during years 2003–2016. Results: A total of 120 patients (15%) are identified as younger than 55 years at first diagnosis with ages ranging from 31 to 55 (median age of 51). FISH results are available in 53 young patients and 167 older patients. Molecular aberrations found in the younger age group compared to older group are as follows: deletions at LAMP1/13q14 (35.8% vs 43.1%, P = .22), CEP12/trisomy 12 (26.4% vs 25.1%, P = .45), deletions of ATM/11q22-23 (16.9% vs 20.3%, P = .37), TP53/17p13 deletion (9.4% vs 17.9%, P = .1), and MYB/6q deletion (5.6% vs 4.8%, P = .55). Conclusion: Our study in younger patients demonstrates lower frequency of cytogenetic aberrations of 11q deletion and TP53/17p deletion, which are typically worse prognostic predictors of CLL/SLL. Although the changes are not statistically significant, this finding may contribute to the better outcomes of the younger patient group. More patients, additional data, and longer follow-up are necessary to determine the importance of these findings.